Aminoglycosides Market Size – By Product, By Application, By Route of Administration, By End Use – Global Forecast, 2025 – 2034

Aminoglycosides Market Size

The global aminoglycosides market size was valued at USD 1.9 billion in 2024 and is estimated to grow at a CAGR of 4% from 2025 to 2034. The rising prevalence of bacterial infections such as urinary tract infections (UTIs), pneumonia, and sepsis are major contributors to the demand for aminoglycosides, as aminoglycosides are commonly used to treat these infections due to their broad-spectrum activity against Gram-negative bacteria, that further contribute to market growth.
 

Moreover, the rise of antibiotic resistance bacteria is a major concern and aminoglycosides like gentamicin and tobramycin are still effective against certain resistant strains, driving their demand in hospitals and healthcare settings, thereby boosting the growth of aminoglycosides market.
 

Furthermore, the market is bolstered by growing advancements in drug delivery systems and medical devices that have enhanced the efficacy of aminoglycosides. Additionally, new formulations and modes of administration such as inhalation of respiratory infections have expanded their application in treatment protocols, contributing to the market growth. In addition, the increasing government initiatives and support in various regions for the use of essential antibiotics through subsidized programs or national healthcare systems, increases the adoption of aminoglycosides based products for the treatment of infectious disease, drives the growth of the market. For instance, programs by organizations like WHO and GAVI (Global Alliance for Vaccines and Immunization) support the distribution of essential antibiotics in underserved regions, leading to an increase in their use. Thus, the increasing usage of aminoglycosides in veterinary medicine, coupled with cost effectiveness and availability of drug fueled the market penetration.
 

Aminoglycosides are a class of antibiotics used mainly in the treatment of aerobic gram-negative bacilli infections, although they are also effective against other bacteria including Staphylococci and Mycobacterium tuberculosis. They are often used in combination with other antibiotics. Aminoglycosides are thought to work by inhibiting protein synthesis inside bacteria.
 

Aminoglycosides Market Trends

The rising prevalence of bacterial infection coupled with technological advancement in aminoglycosides is a significant driver of the market.
 

• There is a growing focus on developing more effective aminoglycoside formulations, including those that reduce nephrotoxicity, a known side effect. These advancements are expected to increase their use and market potential, that is anticipated to boost market growth.
   
• For instance, research shows that approximately 10-20% of patients receiving aminoglycosides experience nephrotoxicity. Thus, the ongoing continuous efforts to reduce these side effects with new formulations are driving innovation in the market.
   
• Additionally, regulatory bodies such as U.S. FDA and European Medicines Agency (EMA) are providing approvals for newer aminoglycoside-based drugs, which is expanding the available product range and driving market growth.
   

Aminoglycosides Market Analysis

Based on product, the global market is divided into neomycin, tobramycin, gentamicin, amikacin, paromomycin, streptomycin, and other products. The gentamicin segment dominated the market and was valued at USD 541.6 million in 2024.
 

• The global rise in multidrug-resistant bacterial diseases has increased the need for potent antibiotics such as gentamicin. For instance, antimicrobial resistance (AMR) is a significant global health concern, with the WHO estimating that AMR could lead to 10 million deaths annually by 2050.
   
• As traditional antibiotics become less effective, healthcare providers are turning to aminoglycosides to combat resistant infections.
   
• Moreover, gentamicin is considered cost-effective compared to newer antibiotics, making it a preferred choice in low- and middle-income countries.
   
• Furthermore, the rise in surgical procedures and hospital-acquired infections (HAIs) has increased the demand for gentamicin as part of combination therapies to reduce infection risks further fueling the need for gentamicin.
   

Based on the application, the aminoglycosides market is categorized into bacterial infection, tuberculosis and other applications. The bacterial infection segment accounted for the highest market share of 65.5% in 2024. The segment is further bifurcated into respiratory infections, skin and soft tissue infection, bone infections, and urinary tract infections (UTIs).
 

• The increase in the number of hospitals acquired infection (HAIs), particularly ventilator-associated pneumonia, urinary tract infections, and bloodstream infections, are often caused by Gram-negative pathogens like Pseudomonas aeruginosa and Klebsiella pneumoniae.
   
• Aminoglycosides are essential in managing HAIs, with studies indicating that nearly 20% of ICU patients experience infections that require aminoglycoside therapy further supports the growth of the market.
   
• Moreover, the growing geriatric population is more susceptible to infections due to a decline in the immune system. This demographic shift has led to an increased need for effective antibacterial treatments, thereby increasing the demand for aminoglycoside antibiotics that further contributes to the growth of the market.
   

Based on the route of administration, the aminoglycosides market is categorized into injectable, oral, topical and ophthalmic. The oral segment dominated the market in 2024 and is growing with a CAGR of 4.1% during the analysis period.
 

• The oral route is non-invasive, making it easier for patients to self-administer drugs compared to injections or intravenous (IV) routes.
   
• Oral aminoglycosides are generally less expensive to manufacture and administer than parenteral formulations. Additionally, oral formulations reduce the need for hospital visits, IV setups, and professional administration, lowering overall healthcare costs.
   
• Oral aminoglycosides are particularly effective for gastrointestinal (GI) infections because they can act directly within the intestinal tract without systemic absorption.
   
• Thus, the global burden of parasitic diseases, such as amebiasis, affects approximately 50 million people annually, driving demand for oral aminoglycosides such as paromomycin, which is used to treat amebiasis and leishmaniasis for its localized action within the gut.
   

Based on end use, the aminoglycosides market is categorized into hospitals and clinics, research and academic institutes, homecare settings, and other end users. The hospitals and clinics segment dominated the market in 2024 and is anticipated to reach USD 1.2 billion by 2034.
 

• Hospitals and clinics treat a large volume of severe bacterial infections such as pneumonia, sepsis, urinary tract infections (UTIs), and meningitis. Aminoglycosides are often used for these hospital-acquired infections (HAIs) due to their broad-spectrum activity against Gram-negative bacteria.
   
• Additionally, hospitals perform a high volume of surgeries annually, increasing the risk of post-operative infections. Aminoglycosides are commonly administered prophylactically to prevent these infections, especially in orthopedic, cardiovascular, and gastrointestinal surgeries.
   
• Moreover, growth in hospital construction and clinic expansion in emerging markets is contributing to higher aminoglycoside prescriptions.
   

In 2024, the U.S. held a significant position in the North America aminoglycosides market and was valued at USD 726.7 million.
 

• The market in the U.S. is propelled by the rising prevalence of bacterial infections. For instance, according to the report published by Centre for Disease Control and Prevention (CDC), over 2.8 million antimicrobial-resistant infections occur annually in the U.S., leading to approximately 35,000 deaths. This has increased the need for potent antibiotics like aminoglycosides, that further contribute to market growth.
   
• Key drivers include an increase in technological advancements with innovations in diagnostic tools and healthcare infrastructure for the detection of severe bacterial infections, enabling more targeted treatment with aminoglycosides.
   
• Moreover, the U.S. government and private sector are investing more in the research and development of new antibiotics, including aminoglycosides, to counteract the threat of resistant pathogens. This investment is leading to better formulations and new indications for aminoglycosides.
   

Germany shows strong growth potential in the aminoglycosides market.
 

• Germany's advanced healthcare infrastructure, established research institutions, and growing government healthcare investments are key drivers that propels the market growth.
   
• Moreover, Germany, like many other developed countries, faces a significant burden of bacterial infections. These include healthcare-associated infections (HAIs), and infections related to chronic diseases.
   
• Additionally, Germany is proactive in tackling antimicrobial resistance (AMR) through awareness campaigns and education. For instance, according to the German Ministry of Health, educational programs and regulations on the responsible use of antibiotics are helping combat the rise of resistant bacteria, thus reinforcing the importance of aminoglycosides that further contributing to market growth.
   

The aminoglycosides market in Asia Pacific is estimated to grow at a CAGR of 4.3% over the next few years.
 

• The growing number of hospitalizations for severe infections and surgeries increases the demand for aminoglycosides, especially in critical care settings. Additionally, the National Health Commission of China reports a year-on-year increase in hospital admissions, particularly in intensive care units, where aminoglycosides are frequently used.
   
• Moreover, the Chinese government is significantly investing in healthcare and research, emphasizing the improvement of national capabilities to improve access to advanced antibiotics, including aminoglycosides.
   
• The increasing elderly population in China is prone to infections due to weakened immune systems, creating more demand for antibiotics like aminoglycosides.
   

Brazil's aminoglycosides market is projected to witness growth in coming years.
 

• Brazil is experiencing significant growth in the market, driven by rapidly expanding healthcare infrastructure, driven by both government initiatives and private investments.
   
• Furthermore, the Brazilian government invests in public health programs aimed at controlling infectious diseases and providing treatment to underprivileged populations. This has led to increased use of antibiotics in both public and private healthcare settings, that contribute to market growth.
   

Saudi Arabia is anticipated to grow in the Middle East and African aminoglycosides market.
 

• Saudi Arabia's healthcare sector is modernizing rapidly, driven by the Vision 2030 initiative. Additionally, the increasing prevalence of chronic disease such as such as diabetes, kidney diseases, and cancer in Saudi Arabia, increases the risk of bacterial infections, thereby increasing the demand for antibiotics like aminoglycosides.
   
• Moreover, Saudi Arabia has implemented various regulations that support the proper use of antibiotics, such as controlled access to prescription drugs, which can help ensure appropriate use of aminoglycosides.
   

Aminoglycosides Market Share

The competitive landscape in the market is characterized by a mix of global pharmaceutical and biotechnology companies and regional players. Established pharmaceutical giants offer well-known aminoglycosides under various brand names. Generic manufacturers in emerging markets further intensify competition by offering cost-effective alternatives. Companies are also investing in R&D to develop novel formulations addressing antimicrobial resistance. Strategic collaborations with healthcare organizations and regulatory bodies enhance market penetration.
 

Aminoglycosides Market Companies

Few of the prominent players operating in the aminoglycosides industry include:

• Aurobindo Pharma
• Bausch Health Companies
• Cipla
• Fresenius Kabi
• Kremoint Pharma (Bliss GVS Pharma)
• Meiji Seika Pharma (Meiji Holdings)
• Novartis
• Perrigo Company
• Pfizer
• Sun Pharmaceutical Industries
• Sanofi
• Teva Pharmaceuticals 
   

Aminoglycosides Industry News

• In February 2024, Cipla Limited received approval from the Central Drugs Standard Control Organization (CDSCO) to market the novel antibiotic plazomicin in India. Plazomicin is a new intravenous (IV) aminoglycoside indicated for the treatment of complicated urinary tract infections (cUTI) including pyelonephritis. Plazomicin’ s introduction in India underscores Cipla's proactive response to the urgent global challenge of antimicrobial resistance (AMR).
   

The aminoglycosides market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Neomycin
• Tobramycin
• Gentamicin
• Amikacin
• Paromomycin
• Streptomycin
• Other products

Market, By Application

• Bacterial infection
  • Respiratory infections
  • Skin and soft tissue infections
  • Bone infections
  • Urinary tract infections (UTIs)
• Tuberculosis
• Other applications

Market, By Route of Administration

• Injectable
• Oral
• Topical
• Ophthalmic

Market, By End Use

• Hospitals and clinics
• Research and academic institutes
• Homecare settings
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE